Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor) (TA257)
Fast, easy summary view of NICE guidance on 'advanced breast cancer'
Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2
NICE does not recommend lapatinib or trastuzumab in combination with an aromatase inhibitor for women who have been through the menopause and who have metastatic breast cancer that is hormone receptor and HER2 positive.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. Lapatinib and trastuzumab do not provide enough benefit to patients to justify their high cost even when the special considerations were applied, so NICE did not recommend them.
- TA257 Breast cancer (metastatic hormone-receptor) - lapatinib and trastuzumab (with aromatase inhibitor): guidance (web format)
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: advanced breast cancer
- None found
This page was last updated: 24 September 2013
- Web format
- Full Guidance (PDF)
- TA257 Lapatinib neu trastuzumab ar y cyd ag atalydd aromatase fel triniaeth gyntaf ar gyfer canser metastatig y fron sy'n dderbynnydd hormonau ac yn HER2 positif: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.